Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update.
Share Talk Bulletin Board Heroes, Thursday 24th October 2019
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update.
Share Talk Bulletin Board Heroes, Tuesday 16th July 2019
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this charting update.
Motif Bio PLC (LON:MTFB) Complete Response Letter from the FDA
Graham Lumsden, Chief Executive Officer of Motif Bio, said: “We are disappointed for patients and providers seeking an alternative antibiotic to treat ABSSSI. We intend to request a meeting with
Share Talk Bulletin Board Heroes: 14th Aug 2018
A charting look at some of the most followed stocks on the London market, Zak Mir covers.
Motif Bio Plc (AIM,NASDAQ:MTFB) Filing of U.S. Shelf Registration
Motif Bio® plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has filed a “universal” shelf registration statement on Form F-3 with
Shard Capital: Insights into the small pharmaceutical company sector (video)
Wealth Manager at Shard Capital Stockbrokers, Simon Niven, provides some insights into the small pharmaceutical company sector.
Motif Bio Plc (NASDAQ,AIM:MTFB) Secures up to US$20 million debt financing
London and New York, Motif Bio plc (AIM/NASDAQ: MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has entered into an agreement for
Motif Bio PLC (AIM:MTFB) Motif Bio Announces Positive Topline Results for iclaprim in the REVIVE-2 Phase 3 Study
Motif Bio plc (AIM/NASDAQ: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced positive topline results from REVIVE-2, a global Phase 3 clinical trial evaluating the
Motif Bio Plc (AIM,NASDAQ:MTFB) Iclaprim granted Orphan Drug Designation by US FDA
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the US Food and Drug Administration (“FDA”) has granted its investigational drug
Motif Bio Plc (AIM:MTFB): Proposed Placing
Motif Bio plc (AIM:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces its intention to raise approximately £19.4 million (US$25 million), before expenses, by way of a